POT1 and diffuse large B-cell lymphoma: Each dog with a POT1 mutation tended to have more than one enriched variant, with a similar observation in TRAF3. Therefore, the novel target drugs against POT1 and TRAF3 might have therapeutic potential for treating DLBCL in dogs.